tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Chimeric Therapeutics Advances CHM CDH17 Clinical Trial with Promising Results

Story Highlights
Chimeric Therapeutics Advances CHM CDH17 Clinical Trial with Promising Results

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Chimeric Therapeutics Ltd. ( (AU:CHM) ) has provided an announcement.

Chimeric Therapeutics has advanced its CHM CDH17 clinical trial to dose level 2, administering 150 million CDH17 CAR-T+ cells, with early results showing anti-tumor activity and no new safety concerns. This progress in their Phase 1/2 trial, targeting advanced colorectal, gastric, and intestinal neuroendocrine tumors, marks a significant step in their efforts to develop a novel CAR-T cell therapy, potentially impacting their market positioning and offering new hope for patients with these challenging cancers.

More about Chimeric Therapeutics Ltd.

Chimeric Therapeutics is a clinical stage cell therapy company based in Australia, recognized as a leader in the cell therapy industry. The company focuses on developing innovative cell therapies for cancer treatment, with a diversified portfolio that includes autologous CAR T cell therapies and allogeneic NK cell therapies. Their assets are being developed across multiple oncology areas, with four clinical stage programs currently underway.

Technical Sentiment Signal: Sell

Current Market Cap: A$11.37M

For a thorough assessment of CHM stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1